PD-L1, an Important Immune Checkpoint Regulator, Is Suppressed by miR-34a in Head and Neck Squamous Cell Carcinoma

Kenjiro Higashi  
Tohoku Daigaku

Takenori Ogawa  
Tohoku Daigaku

Yuriko Saiki  
Tohoku Daigaku

Tomohiko Ishikawa  
Tohoku Daigaku

Yuta Kobayashi  
Tohoku Daigaku

Akira Ohkoshi  
Tohoku Daigaku

Ayako Nakanome  
Toho Daigaku

Yukio Katori  
Tohoku Daigaku

Akira Horii (horii@med.tohoku.ac.jp)  
Tohoku University School of Medicine  https://orcid.org/0000-0002-3967-3291

Research article

Keywords: PD-L1, miR-34a, TP53, head and neck squamous cell carcinoma

DOI: https://doi.org/10.21203/rs.3.rs-25255/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
**Abstract**

**Background:** Key molecules regulating the immune checkpoint have shed light on the efforts to control several cancers. Recently, immune checkpoint inhibitors for cancer therapy such as antibodies against programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) have been developed. In head and neck squamous cell carcinomas (HNSCCs), such immune checkpoint inhibitors have come into clinical use and are expected to improve patients’ prognoses. Recently, *miR-34a* has been shown to be a downstream micro RNA of TP53 that regulates PD-L1 in several types of cancer. To reveal the correlations between *miR-34a* and PD-L1 in HNSCCs in terms of clinical significance, we analyzed 19 HNSCC cell lines.

**Methods:** We measured the expression levels of *miR-34a* and PD-L1 in 10 HNSCC cell lines as well as in 9 of their derived acquired cisplatin (CDDP) resistant cell lines by qRT-PCR and Western blotting. Results were further analyzed by their TP53 statuses. We also investigated the changes in PD-L1 expression levels after *miR-34a* precursor- or inhibitor-mediated forced expression or suppression in HNSCC cell lines.

**Results:** We observed inverse correlations between both mRNA and protein expression levels of *miR-34a* and PD-L1. No significant differences in *miR-34a* levels were observed with regard to TP53 status. Forced expression of *miR-34a* decreased PD-L1 expression, and suppression of *miR-34a* increased PD-L1 expression.

**Conclusion:** Our present results suggest that *miR-34a* negatively regulates PD-L1 expression, possibly in a TP53 independent manner in HNSCC.

**Background**

Head and neck squamous cell carcinoma (HNSCC) is the sixth most commonly diagnosed cancer and the eighth most common cause of cancer death worldwide [1]. Although molecular target therapy has been utilized lately, surgical resection and/or a combination of cisplatin-based chemo-radiotherapy or sole radiotherapy are the major therapeutic strategies for patients with HNSCC. However, poor survival rates are still reported in advanced stage patients. Recently, functions of immune checkpoint proteins such as programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) in the cancer cells have been elucidated, and inhibitory antibodies against those immune checkpoint molecules have been developed [2, 3]. In HNSCC, anti-PD-1 antibody nivolumab and pembrolizumab have been shown to be clinically effective [4, 5].

Micro RNAs (miRNAs) are a class of small noncoding RNA molecules, typically 18–25 nucleotides long, known to be among the factors regulating gene functions. miRNAs are found to play important roles in proliferation, differentiation, and migration [6, 7], and some of them work critically for suppression of carcinogenesis. *miR-34a* is known to be one of the downstream molecules of TP53 and functions as a tumor suppressor [8–11]. It could be a prognostic marker in sinonasal squamous cell carcinoma treated
with cisplatin (CDDP)-based chemoradiotherapy [12]. A number of genes targeted by miR-34a have been identified [13–15], and PD-L1 was included in one such target gene in non-small cell lung cancer and acute myeloid leukemia [16, 17]. In this study, we investigated the relationship between miR-34a and PD-L1 in HNSCC.

**Methods**

**Cell lines**

We utilized a total of ten HNSCC cell lines (RPMI2650, HSC2, HSC3, HSC4, IMC3, IMC4, Ho1-u-1, SAS, Ca9-22, HSQ89) as well as nine their derived and previously established acquired CDDP resistant cell lines (RPMI2650CR, HSC2CR, HSC3CR, HSC4CR, IMC4CR, Ho1-u-1CR, SASCR, Ca9-22CR, HSQ89CR) [18, 19]. Culture conditions of these 19 cell lines were described previously [18, 19].

**Rna Preparation**

Preparation of miRNAs and total RNAs were done using mirVana miRNA Isolation kit (Applied Biosystems, Foster City, CA) and the RNeasy Mini Kit (QIAGEN, Tokyo, Japan) according to the manufacturers' instructions, and the quality of the extracted RNAs was monitored by Bioanalyzer (Agilent Technologies, Santa Clara, CA).

**Quantitative Reverse Transcription-polymerase Chain Reaction (qrt-pcr)**

qRT-PCR experiments were performed according to methods described previously [12]. In brief, quantification of miR-34a was assessed by TaqMan microRNA assay kit and an ABI PRISM 7000 Sequence Detection System (Applied Biosystems). Results were normalized by ΔCt methods, and the RNU44 level was monitored as the internal control. Using ROX Mix (Thermo Fisher Scientific, Tokyo, Japan), 2 μg of total RNA from each sample was used for cDNA synthesis and qRT-PCR analyses for detection of PD-L1 expression levels. Signals were detected by an ABI PRISM 7000 Sequence Detection System, and expression levels were normalized by ΔΔCt methods using beta-2-microglobulin (B2M) as the internal control [20]. The PD-L1 primer pairs and the probe used for qRT-PCR are as follows: forward primer, 5’-CCC AGT TCT GCG CAG CTT C-3’; reverse primer, 5’-AGC AAA TAT CCT CAT CTT TCT G-3’; and probe, 5’-CGC GCT TCT GTC CGC CTG CAG-3’. All of these experiments were performed in triplicate.

**Western Blotting**

Western blotting analyses were performed as described previously [21]. In brief, total proteins from the collected cell were extracted, both before treatment and 16 hours after treatment, with 1 μg/ml of doxorubicin, then electrophoresed on a SuperSep Ace 5–20% polyacrylamide gradient gel (Wako, Osaka, Japan), transferred to a PVDF membrane (ATTO, Tokyo, Japan), and blocked by skim milk. Then the membrane was incubated overnight at 4°C with one of the following primary antibodies: rabbit anti-human PD-L1 monoclonal antibody [28–8] (Abcam, Tokyo, Japan), mouse anti-human p53 monoclonal
antibody DO-7 (DAKO, Glostrup, Denmark), or mouse anti-ActB monoclonal antibody (Sigma, St. Louis, MO). Horseradish peroxidase (HRP) conjugated secondary antibodies (Amersham Biosciences, Little Chalfont, UK) were used against corresponding primary antibodies (rabbit or mouse). Signals were visualized using Enhanced ChemiLuminescence (ECL) Detection Reagent (Amersham) and digitally processed using ImageQuant LAS 4000 (GE Healthcare, Tokyo, Japan). The band intensities were digitalized by the ImageQuant software (GE Healthcare), and relative intensities were calculated by normalization using β-actin (ACTB) as the internal control.

**Transfection of miR-34a precursor or inhibitor to the cell lines**

Cell lines were seeded into six-well plates at a density of $2 \times 10^5$ cells per well and grown overnight. Then either the *miR-34a* precursor (Ambion Pre-miR miRNA Precursor) or the *miR-34a* inhibitor (Ambion Anti-miR miRNA Inhibitor) was transfected at the final concentration of 12.5 nM using 7.5 µL RNAiMAX transfection reagent. After 72 hours, cell pellets were collected for further investigation.

**Statistical analysis**

Statistical analyses were done using Microsoft excel for Mac (ver.16.32 (19120802)) and R for Mac (R 3.5.2 GUI 1.70 El Capitan build (7612)). The Spearman's rank correlation, Kruskal-Wallis test and Welch's t test analyses were carried out. Significant difference was considered as $P < 0.05$.

**Results**

**Expressional analyses of miR-34a in the cell lines**

Initially, expression levels of *miR-34a* in the cell lines were investigated (Fig. 1). Relative expression levels of *miR-34a* (*miR-34a/RNU44* ratio) significantly varied among cell lines ($0.0097-2.07$, median: $0.042$, $P < 0.001$ by Kruskal-Wallis test), and ratios of 0.1 or more were observed in seven cell lines (RPMI2650, HSQ89, HSQ89CR, IMC4, IMC4CR, IMC3 and HSC2CR).

**Expression Analyses Of PD-L1 mRNA And Protein**

We then investigated the mRNA and protein expression levels of PD-L1 (Figs. 2a and 2b). Relative mRNA expression levels of *PD-L1* (*PD-L1/B2M* ratio) significantly varied among cell lines ($0.000112-0.0494$ median: $0.00198$, $P < 0.001$ by Kruskal-Wallis test), and ratios of 0.1 or more were observed in six cell lines (HSC2, HSC2CR, HSC3, HSC4CR, SAS and SASCR).

**Analyses of the relationships between miR-34a and PD-L1 expressions**

The relationships between *miR-34a* and PD-L1 mRNA and protein were analyzed (Figs. 2c and 2d). No discrepancies between mRNA and protein expression levels were evident in PD-L1. HSC2, HSC3, HSC3CR, SAS, and SASCR showed high PD-L1 mRNA expression relative to *miR-34a*. In contrast, RPMI2650, HSQ89, IMC4 and IMC4CR showed higher expressions of *miR-34a* relative to PD-L1. It is notable that (1)
we observed significant inverse associations between expression levels of miR-34a and PD-L1 (mRNA: $r = -0.4684 \ P = 0.04476$, protein: $r = -0.7439 \ P = 0.0003931$), and that (2) we did not observe any coherence of miR-34a expression levels between parental and resistant cells.

**Forced expression of miR-34a**

Next, we induced forced expression using miR-34a precursor into the cell lines with lower expressions of miR-34a. We selected three cell lines, HSC2, HSC3 and HSC3CR, and analyzed their expressional changes of PD-L1 after introduction of miR-34a precursor. We observed significantly decreased PD-L1 mRNA expression levels in response to the increase of miR-34a in HSC3 and HSC3CR (Figs. 3a and 3b). These results are in good accordance with those in Fig. 2.

**Inhibition of miR-34a**

In an opposite manner, we also performed suppression experiments using miR-34a inhibitor. We selected four cell lines with the higher expression of miR-34a, RPMI2650, HSQ89, IMC4 and IMC4CR; results are shown in Figs. 3c and 3d. We observed significantly increased PD-L1 mRNA expression levels in response to the decrease in miR-34a levels in RPMI2650 and IMC4CR. Again, these results are in good accordance with those in Fig. 2.

**Elucidation of miR-34a in association with TP53**

Because the regulation of miR-34a in association with TP53 has been reported [22], the statuses of TP53 in 10 HNSCC cell lines and a representative CDDP resistant RPMI2650CR were sequenced for exons 5–8 to detect mutations. Results are shown in Fig. 4a. Then we analyzed protein expression levels of TP53 by Western blotting with and without doxorubicin treatments; results are shown in Fig. 4a. Three of five cell lines without TP53 mutation (RPMI2650, IMC4, and IMC3) increased their protein expression levels after doxorubicin treatment, but no significant differences of miR-34a levels were detected irrespective of TP53 status (Fig. 4b).

**Discussion**

In this study, we demonstrated an inverse correlation between expression levels of miR-34a and PD-L1 in HNSCC cells. Forced expression of miR-34a decreased PD-L1 expression, and introduction of an inhibitor of miR-34a increased PD-L1. These results suggest that miR-34a is one of the important molecules in regulation of PD-L1 in HNSCCs, possibly in an TP53 independent manner.

PD-L1 is reported as a ligand that specifically binds to PD-1 [23]. Its important role is to suppress the immune system by binding to PD-1. A number of cancer cells express PD-L1, which results in escape from immune cells, and such cancer cells can survive. Some reports have demonstrated a significant association between PD-L1 expression and poor prognosis in various malignant tumors [24–28]. Chen et al. [29] showed that PD-L1 expression was regulated by oncogenic pro-survival signaling pathways, such as MAPK or PI3K/Akt pathways. Several investigators have also reported correlations between miR-34a
and PD-L1 expressions. Wang Xi et al. [16] suggested that \textit{miR-34a} can regulate PD-L1 expression by targeting \textit{PD-L1} mRNA in acute myeloid leukemia, and Cortez et al. [17] found that TP53 regulates PD-L1 via \textit{miR-34a}, which directly binds to the 3’ untranslated region of \textit{PD-L1} in non-small cell lung cancer.

\textit{miR-34a} is known as a tumor suppressing miRNA and its role as the tumor suppressor in HNSCC has been reported [30, 31]. In sinonasal squamous cell carcinomas, \textit{miR-34a} expression can be an independent prognostic biomarker in patients undergoing \textit{cis}-diamminedichloroplatinum treatment [12]. One of the key findings in the present study is that the expression levels of PD-L1 and \textit{miR-34a} inversely associated in HNSCC; this result suggests that the PD-L1 opposes \textit{miR-34a}. This is in good agreement with previous reports that \textit{miR-34a} may downregulate PD-L1 expression in squamous cell carcinoma [16, 17]; this should lead to a better prognosis.

Various clinical trials of the immune checkpoint inhibitors have been performed recently, and the expression levels of the immune checkpoint proteins such as PD-L1 or tumor mutation burden are sometimes discussed as indications of such immune checkpoint inhibitors in HNSCCs [32]. We analyzed \textit{miR-34a}, which has been reported as one of the downstream genes of TP53 [22], but the expression levels of \textit{miR-34a} were found to be independent of TP53 statuses in the present study; expression levels of \textit{miR-34a} varied among cells with wild-type TP53, and no significant associations were observed. It is reported that methylation-induced silencing of \textit{miR-34a} is associated with chemoresistance in prostate cancer [33] and that \textit{miR-34a} promoter methylation and \textit{TP53} polymorphisms may be associated with colorectal cancer pathogenesis [34]. However, the numbers of available cells were limited and further investigations are needed.

In this study, we demonstrated that \textit{miR-34a} is one of the important molecules in regulation of immune checkpoint proteins, but further genetic and epigenetic studies, including upstream and downstream molecules of the \textit{miR-34a} family, will contribute to better clinical management of patients with HNSCC.

**Conclusion**

In HNSCC cells, \textit{miR-34a} negatively controls the PD-L1 function, possibly independently from TP53 status. These results may contribute to open a pathway for novel and efficient ways to treat patients with HNSCC.

**List Of Abbreviations**

ACTB: β-actin; CDDP: cisplatin; CTLA4: cytotoxic T-lymphocyte associated protein 4; ECL: enhanced chemiluminescence; HNSCC: head and neck squamous cell carcinoma; HRP: horseradish peroxidase; miRNA: micro RNA; PD-1: programmed cell death 1; PD-L1: programmed cell death 1 ligand 1; qRT-PCR: quantitative reverse transcription-polymerase chain reaction

**Declarations**
**Ethics approval and consent to participate**

This study was approved by Ethics Committee in Tohoku University School of Medicine under the accession numbers of 2018-1-084 and 2018-1-085, and all patients provided written informed consent for this study.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors have no competing interests to declare.

**Funding**

This work was supported in part by Grant-in-Aid from JSPS KAKENHI (16K11221, 16K11222, 26460468, 26462074, 26462595). The role of the funding body: in collection of samples and data, analysis, and writing the manuscript.

**Authors' contributions**

TO, YS, YK, and AH made the research plan. KH, TO, TI, YK, AO, AN, and YK contributed to collecting patients’ samples. KH and TI contributed to collecting data, and TO, YS, and AH supervised experiments. KH, TO, YS, YK, and AH contributed data analysis. KH wrote the manuscript draft, and the draft was brushed-up by KH, TO, YS, and AH. All authors read and approved the final manuscript.

**Acknowledgements**

We are grateful to Dr. B. L. S. Pierce (University of Maryland University College) for editorial work in the preparation of this manuscript, and to Biomedical Research Core (Tohoku University School of Medicine) for technical support.

**References**

1. Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: A focus on human papillomavirus. J Dent Res. 2007;86:104-14.

2. Kolar P, Knieke K, Hegel JK, Quandt D, Burmester GR, Hoff H, Brunner-Weinzierl MC. CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum.
3. Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015;27:39–46.

4. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-67.

5. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Pyriri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet. 2019;394:1915-28.

6. Le MT1, Xie H, Zhou B, Chia PH, Rizk P, Um M, Udolph G, Yang H, Lim B, Lodish HF. MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol. Cell. Biol. 2009;29:5290-305.

7. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005;436:214-20.

8. Cheng CY, Hwang CI, Comey DC, Flesken-Nikitin A, Jiang L, Öner GM, Munroe RJ, Schimenti JC, Hermeking H, Nikitin AY. miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep. 2014;6:1000-7.

9. Shi Y, Liu C, Liu X, Tang DG, Wang J. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS One. 2014;9:e90022.

10. Gao J, Li N, Dong Y, Li S, Xu L, Li X, Li Y, Li Z, Ng SS, Sung JJ, Shen L, Yu J. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. Oncogene. 2015;34:4142-52.

11. Gougelet A, Sartor C, Bachelot L, Godard C, Marchiol C, Renault G, Tores F, Nitschke P, Cavard C, Terris B, Perret C, Colnot S. Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations. Gut. 2016;65:1024-34.

12. Ogawa T, Saiki Y, Shiga K, Chen N, Fukushima S, Sunamura M, Nagase H, Hashimoto S, Matsuura K, Saijo S, Kobayashi T, Hori A. miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. Cancer Sci. 2012;103:1737-43.

13. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007;26:5017–22.

14. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A. 2008;105:13421–6.

15. Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, Zhong Y, Kim SY, Bennett MJ, Chen C, Ozturk A, Hicks GG, Hannon GJ, He L. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol.
16. Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y, Wei J, Chen X, Weng Y, He T, Zhang H. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2015;27:443-52.

17. Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 2016;108: djv303.

18. Ogawa T, Furukawa T, Shiga K, Hashimoto S, Ogawa K, Kobayashi T, Horii A. A cDNA microarray analysis identifies 52 genes associated with CDDP susceptibility in head and neck squamous cell carcinoma cell lines. Eur Arch Otorhinolaryngol. 2010;267:123-9.

19. Ogawa T, Ogawa K, Shiga K, Furukawa T, Nagase H, Hashimoto S, Kobayashi T, Horii A. Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2010;267:1599-606.

20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods. 2001;25: 402-8.

21. Kondo E, Horii A, Fukushige S. The human PMS2L proteins do not interact with hMLH1, a major DNA mismatch repair protein. J Biochem. 1999;125:818-25.

22. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17: 193–9.

23. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-34.

24. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174-9.

25. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M, Nakajima Y. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11:2947-53.

26. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108:19-24.

27. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007;56:1173-82.

28. Nom T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1
28. Liao H, Xiao Y, Hu Y, Xiao Y, Yin Z, Liu L, Kang X, Chen Y. Methylation-induced silencing of miR-34a enhances chemoresistance by directly upregulating ATG4B-induced autophagy through AMPK/mTOR pathway in prostate cancer. Oncol Rep. 2016;35:64-72.

29. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: A novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27:409-16.

30. Zhang J, Wang Y, Chen X, Zhou Y, Jiang F, Chen J, Wang L, Zhang WF. MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC). Oncotarget. 2015;6:7454-69.

31. Xie X, Piao L, Bullock BN, Smith A, Su T, Zhang M, Teknos TN, Arora PS, Pan Q. Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma. Oncogene. 2014;33:1037-46.

32. Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48: 434-52.

33. Jun HH, Kwack K, Lee KH, Kim JO, Park HS, Ryu CS, Lee JY, Ko D, Kim JW, Kim NK. Association between TP53 genetic polymorphisms and the methylation and expression of miR-34a, 34b/c in colorectal cancer tissues. Oncol Lett. 2019;17:4726-34

**Figures**
Expression levels of miR-34a in HNSCC cell lines analyzed in this study are shown. Expression of RNU44 is monitored as the control, and relative expression levels (miR-34a/RNU44 ratio) are displayed; significantly varied expression levels among cell lines were observed (0.0097-2.07, median: 0.042, P < 0.001) by Kruskal-Wallis test.
Expression levels of PD-L1 in HNSCC cell lines analyzed in this study are shown. Expression of beta-2-microglobulin (B2M) is used as the control, and relative expression levels (miR-34a/RNU44 ratio) are displayed; significantly varied expression levels among cell lines were observed (0.000112-0.0494 median: 0.00198, P < 0.001) by Kruskal-Wallis test. (b) Protein expression levels of PD-L1 by Western blotting are shown. Expression of beta-actin (ACTB) is used as the control. Full-length blots/gels are presented in Supplementary Figure 2b. (c) Relationship between miR-34a and PD-L1 mRNA in each cell line is plotted as a point diagram. (d) Relationship between miR-34a and PD-L1 protein in each cell line is plotted as a point diagram.
Figure 3

Results of introduction of miR-34a precursor (a, b) or inhibitor (c, d) into HNSCC cell lines. (a) Expression levels of miR-34a after precursor transfection. (b) Expression levels of PD-L1 mRNA after precursor transfection. (c) Expression levels of miR-34a after inhibitor transfection. (d) Expression levels of PD-L1 mRNA after inhibitor transfection. *, **, ***, and **** denote $P < 0.05$, $P < 0.01$, $P < 0.005$, and $P < 0.001$, respectively.
Figure 4

(a) Expression of TP53 with and without treatment of doxorubicin in HNSCC cell lines. TP53 mutation status in exons 5-8 for each cell line is also indicated. Expression of beta actin (ACTB) is used as the control. M, protein size marker; -, without doxorubicin treatment; +, with doxorubicin treatment. Full-length blots/gels are presented in Supplementary Figure 4a. (b) Box and whisker plot of miR-34a expression
after doxorubicin treatment in association with TP53 mutation status. Maximum number, 25% percentile, median, 75% percentile and minimum numbers are shown in box and whisker plots.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryFig4a.tif
- SupplementaryFig2b.tif